IM Cannabis (IMCC) Projected to Post Earnings on Monday

IM Cannabis (NASDAQ:IMCC) is anticipated to announce its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of $0.0860 per share and revenue of $15.6620 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, April 3, 2026 at 9:00 AM ET.

IM Cannabis Trading Down 5.3%

IMCC opened at $0.62 on Monday. The company has a quick ratio of 0.56, a current ratio of 0.82 and a debt-to-equity ratio of 0.25. IM Cannabis has a 52 week low of $0.54 and a 52 week high of $7.12. The business’s 50 day moving average is $1.05 and its two-hundred day moving average is $1.45. The firm has a market cap of $3.65 million, a price-to-earnings ratio of -0.79 and a beta of 2.17.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of IM Cannabis in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, IM Cannabis presently has an average rating of “Sell”.

Institutional Trading of IM Cannabis

A hedge fund recently bought a new stake in IM Cannabis stock. DRW Securities LLC purchased a new position in shares of IM Cannabis Corp. (NASDAQ:IMCC) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 23,060 shares of the company’s stock, valued at approximately $32,000. DRW Securities LLC owned 0.39% of IM Cannabis as of its most recent SEC filing. Institutional investors own 7.68% of the company’s stock.

IM Cannabis Company Profile

IM Cannabis Corp is a vertically integrated medical cannabis company based in Israel, specializing in the research, cultivation and production of cannabis-based formulations. The company holds three key licenses granted by the Israeli Ministry of Health, covering cultivation, possession and distribution of medical-grade cannabis. Its production facilities in Moshav Yizrael feature controlled-environment agriculture chambers designed to deliver consistent, high-purity cannabinoid profiles.

The company’s product portfolio includes standardized cannabis oils, distillates, vaporizer cartridges and topical preparations, all formulated under Good Manufacturing Practice (GMP) standards.